The current status of HPV DNA testing

Infection with high-risk types of HPV underlies most cases of high-grade cervical intraepithelial neoplasia (CIN) and practically all cases of invasive cervical cancer. Currently, cervical HPV DNA is detected by means of PCR and sandwich capture molecular hybridization methods. Research has focused on the potential role of HPV testing in three conditions: screening for cervical neoplasia, triage of women with low-grade lesions and follow-up after conservative surgical treatment for CIN. Concerning the first condition, HPV testing does not seem to offer an obvious advantage over traditional cytology screening, mainly due to false positive results in younger women with transient HPV infection. A possible exemption to this is the case of middle-aged women and low-resource settings, where the excellent sensitivity of a HPV test is desirable. Although data are controversial regarding low grade lesions, results from randomized studies indicate that HPV testing could be useful in a triage of women with an initial cytological diagnosis of ASCUS, where detection of DNA of a high-risk type should lead to colposcopy. Although there is a lack of randomized controlled trials in this field, data from observational studies indicate that HPV DNA testing after conservative surgical treatment for CIN may be very sensitive and detect early residual and recurrent disease.

HPV; PCR; Hybrid Capture; Screening; Triage; Follow-up

[1] Macgregor J.E., Campbell M.K., Mann E.M., Swanson K.Y.: "Screening for cervical intraepithelial neoplasia in north east Scotland shows fall in incidence and mortality from invasive cancer with concomitant rise in preinvasive disease". Br. Med. J., I 994, 308 (6941), 1407.

[2] Parkin D.M., Pisani P., Ferlay J.: "Global cancer statistics". CA Cancer J. Clin., 1999, 49 (1), 33, I.

[3] Fahey M.T., Irwig L., Macaskill P.: "Meta-analysis of Pap test accuracy". Am. J. Epidemiol., 1995, 141 (7), 680.

[4] Lorincz A.T., Reid R., Jenson A.B., Greenberg M.D., Lancaster W., Kurman R.J.: "Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types". Obstet. Gynecol., 1992, 79 (3), 328.

[5] Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V. et al.: "Human papillomavirus is a necessary cause of invasive cervical cancer worldwide". J. Pathol., l 999, 189 (1), 12.

[6] van Muyden R.C., ter Harmsel B.W., Smedts F.M., Hermans J., Kuijpers J.C., Raikhlin N.T. et al.: "Detection and typing of human papillomavirus in cervical carcinomas in Russian women: a prognostic study". Cancer, 1999, 85 (9), 2011.

[7] Schiffman M.H., Brinton L.A.: "The epidemiology of cervical carcinogenesis". Cancer, I 995, 76 (suppl. 10), 1888.

[8] Bosch F.X., Munoz N.: "The viral etiology of cervical cancer". Virus Res., 2002, 89 (2), 183.

[9] Elfgren K., Bistoletti P., DilIner L., Walboomers J.M., Meijer C.J., Dillner J.: "Conization for cervical intraepithelial neoplasia is followed by disappearance of human papillomavirus deoxyribonucleic acid and a decline in serum and cervical mucus antibodies against human papillomavirus antigens". Am. J. Obstet. Gynecol., 1996, 174 (3), 937.

[10] de Villiers E.M., Wagner D., Schneider A., Wesch H., Miki aw H., Wahrendorf J. et al.: "Human papillomavirus infections in women with and without abnormal cervical cytology". Lancet, 1987, 2 (8561), 703.

[11] Lazcano-Ponce E., Herrero R., Munoz N., Cruz A., Shah K.V., Alonso P. et al.: "Epidemiology of HPV infection among Mexican women with normal cervical cytology". Int. J. Cancer, 2001, 91 (3), 412.

[12] Depuydt C.E., Vereecken A.J., Salem bier G.M., Vanbrabant A.S., Boels L.A. et al.: "Thin-layer liquid based cervical cytology and PCR for detecting and typing human papillomaviruw DNA in Flemish women". Br. J. Cancer, 2003, 88 (4), 560.

[13] Reid R., Lorincz A.T.: "Human papillomavirus tests". Baillie res Clin. Obstet. Gynaecol., 1995, 9 (I), 65

[14] Chua K.L., Wiklund F., Lenner P., Angstrom T., Hallmans G., Bergman F. et al.: "A prospective study on the risk of cervical intraepithelial neoplasia among healthy subjects with serum antibodies to HPV compared with HPV DNA in cervical smears". Int. J. Cancer, 1996, 68 (I), 54

[15] Olsen A.O., Dillned:, Gjoen K., Sauer T., Orstavik I., Magnus P.: "A population-based case-control study of hum_an papillomavirus-type-16 seropositivity and incident high-grade dysplasia of the uterine cervix". Int. J. Cancer, 1996, 68 (4), 415

[16] Sun Y., Eluf-Neto J., Bosch F.X., Munoz N., Walboomers J.M., Meijer C.J. et al.: "Serum antibodies to human papillomavirus 16 proteins in women from Brazil with invasive cervical carcinoma". Cancer Epidemiol. Biomarkers Prev., 1999, 8 (10), 935.

[17] Ferris D.G., Wright T.C. Jr., Litaker M.S., Richart R.M., Lorincz A.T., Sun X.W. et al.: "Comparison of two tests for detectmg carcinogenic HPV in women with Papanicolaou smear reports of ASCUS and SIL". J. Fam. Pract., 1998, 46 (2), 136

[18] Lorincz A.T.: "Molecular methods for the detection of human papillomavirus infection". Obstet. Gynecol. Clin. N. A., 1996, 23(3), 707.

[19] (No authors listed). "Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. The Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group". J. Natl. Cancer Inst., 2000, 92 (5), 397.

[20] Venturoli S., Cricca M., Bonvicini F., Giosa F., Pulvirenti F.R. Galli C. et al.: "Human papillomavirus DNA testing by PCR-ELISA and hybrid capture II from a single cytological specimen : concordance and correlation with cytological results". J. Clin. Viral., 2002, 25, 177.

[21] American College of Obstetricians and Gynecologists: "ACOG technology assessment in Obstetrics and Gynecology". Number 2, December 2002. American College of Obstetricians and Gynecologists. Obstet. Gynecol., 2002,100 (6), 1423.

[22] Agency for Health Care Policy and Research. Evaluation of cervical cytology. Evidence Report/Technology Assessment 5. Rockville (MD): AHCPR; 1999. Publication no. 99-EOl O.

[23] Jones B.A., Novis D.A.: "Cervical biopsy-cytology correlation. A College of American Pathologists Q-Probes study of 22 439 correlations in 348 laboratories". Arch. Pathol. Lab. Med., 1996, 120 (6), 523.

[24] Ronnett B.M., Manos M.M., Ransley J.E., Fetterman B.J., Kinney W.K., Hurley L.B. et al.: "Atypical glandular cells of undetermined significance (AGUS): cytopathologic features, histopathologic results, and human papillomavirus DNA detection". Hum Pathol., 1999, 30 (7), 816.

[25] Lonky N.M., Sadeghi M., Tsadik G.W., Petitti D.: "The clinical significance of the poor correlation of cervical dysplasia and cervical malignancy with referral cytologic results". Am. J. Obstet. Gynecol., 1999, 181, 560.

[26] Hong LS., Marshalleck J., Williams R.H., Gaiter T.E., Mielzynska-Lohnas I., Kim K.: "Comparative analysis of a liquid-based Pap test and concurrent HPV DNA assay of residual samples. A study of 608 cases". Acta Cytol., 2002, 46 (5), 828.

[27] Rosendaal L., Walboomers J.M.M., van der Linden J.C., Voorhorst F.J., Kenemans P., Helmerhorst T.H.J.M. et al.: "PCR based high risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervi smears". Int. J. Cancer, 1996, 68, 766.

[28] Paraskevaidis E., Davidson E.J., Malamou-Mitsi V., Hirsch P.M., Pappa L., Koliopoulos G., Lolis E., Zikopoulos K., Paschopoulos M., Doussias V., Agnantis N.: "An observational study of women with positive HPV-DNA tests and normal cytology and colposcopy". Eur. J. Gynaecol. Oneal., 2002, 23 (4), 320.

[29] Carozzi F., Ronco G., Confortini M., Noferini D., Maddau C., Ciatto S. et al.: "Prediction of high-grade cervical intraepithelial neoplasia in cytologically normal women by human papillomavirus testing". Br. J. Cancer, 2000, 83 (11), 1462.

[30] Schneider A., Hoyer H., Lotz B., Leistritza S., Kuhne-Heid R., Nindl L et al.: "Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy". Int. J. Cancer, 2000, 89 (6), 529.

[31] Ratnam S.,Franco E.L, Ferenczy A.: "Human papillomavirus testing for primary screening of cervical cancer precursors". Cancer Epidemiol. Biomarkers. Prev., 2000, 9 (9), 945.

[32] Kuhn L, Denny L, Pollack A., Lorincz A., Richart R.M., Wright T.C.: "Human papillomavirus DNA testing for cervical cancer screening in low-resource settings". J. Natl. Cancer Inst., 2000, 92 (10), 818.

[33] Clave! C., Masure M., Bory J.P., Putaud I., Mangeonjean C., Lorenzato M. et al.: "Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women". Br. J. Cancer, 2001, 84 (12), 1616.

[34] Kulasingam SL, Hughes J.P., Kivi at N.B., Mao C., Weiss N.S., Kupers J.M. et al.: "Evaluation of human papillornavirus testing in primary screening for cervical abnormalities". JAMA, 2002, 288 (14), 1749.

[35] Paraskevaidis E.,Malamou-Mitsi V.,Koliopoulos G., Pappa L., Lolis E., Georgiou L, Agnantis N.J.: "Expanded cytological referral criteria for colposcopy in cervical screening: comparison with human papillornavirus testing". Gynecol. Oneal., 2001, 82 (2), 355.

[36] Schiffman M., Herrero R., Hildesheim A., Sherman M.E., Bratti M., Wacholder S. et al.: "HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica". JAMA, 2000, 283 (1), 87.

[37] Goldie S.J., Kuhn L., Denny L., Pollack A., W right T.C.: "Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness". JAMA, 2001, 285 (24), 3107.

[38] Lytwyn A., Sellors J.W., Mahony J.B., Daya D., Chapman W., Ellis N. et al.: "Comparison of human papillomavirus DNA testing and repeat Papanicolaou test in women with low-grade cervical cytologic abnormalities: a randomized trial. HPV Effectiveness in Lowgrade Paps (HELP) Study No. 1 Group". CMAJ, 2000, 163 (6), 701.

[39] Solomon D., Schiffman M., Tarone R., ALTS Study group: "Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial". J. Natl. Cancer Inst., 2001, 93 (4), 293.

[40] Kim JJ., Wright T.C., Goldie SJ.: "Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance". JAMA, 2002, 287 (18), 2382.

[41] Wright T.C. Jr., Cox J.T., Massad LS., Twiggs L.B., Wilkinson E.J., ASCCP-Sponsored Consensus Conference. 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA, 2002, 287 (16), 2120.

[42] Martin-Hirsch PL., Paraskevaidis E., Kitchener H.: "Surgery for cervical intraepithelial neoplasia (Cochrane Review)". In: The Cochrane Library, Issue 3, 2002. Oxford: Update Software.

[43] Soutter W.P., de Barros Lopes A., Fletcher A., Monaghan J.M., Duncan I.D., Paraskevaidis E. et al.: "Invasive cervical cancer after conservative therapy for cervical intraepithelial neoplasia". Lancet, 1997, 349 (9057), 978.

[44] Paraskeva汕s E., Koliopoulos G., Alamanos Y., Malamou-Mitsi V., Lolis E.D., Kitchener H.C.: "Human Papillomavirus testing in the prediction of the outcome of treatment for cervical intraepithelial neoplasia". Obstet. Gynecol., 2001, 98 (5 Pt I), 833.

[45] Paraskevaidis E., Lolis E.D., Koliopoulos G., Alamanos Y., Fotiou S., Kitchener H.C.: "Cervical intraepithelial neoplasia outcomes after large loop excision with clear margins". Obstet. Gynecol., 2000, 95 (6 Pt 1), 828.

[46] Paraskeva心s E., Kalantaridou S.N., Paschopoulos M., Zikopoulos K., Lolis E.D., Dalkalitsis N. et al.: "Factors affecting outcome

after incomplete excision of cervical intraepithelial neoplasia". Eur. J. Gynaecol. Oneal., 2003 (in press).

[47] Elfgren K, Jacobs M., Walboomers J.M., Meijer CJ., Dillner J.: "Rate of human papillomavirus clearance after treatment of cervical intraepithelial neoplasia". Obstet. Gynecol., 2002, 100 (5 Pt I), 965.

[48] Paraskeva心s E., Kitchener H., Adonakis G., Parkin D., Lolis D.: "Incomplete excision of CIN in conization: further excision or conservative management'1". Eur. J. Obstet. Gynecol. Reprod. Biol., 1994, 53 (1), 45.

[49] Chua KL., Hjerpe A.: "Human papillomavirus analysis as a prognostic marker following conization of the cervix uteri". Gynecol. Oncol., 1997, 66 (1), 108.

[50] DiStefano AL, Picconi M.A., Alonio L.V., Dalbert D., Mural J., Bartt 0. et al.: "Persistence of human papillomavirus DNA in cervical lesions after treatment with diathermic large loop excision". Infect. Dis. Obstet. Gynecol., 1998, 6 (5), 214.

[51] Bollen L.J., Tjong-A-Hung S.P., van der Velden J., Mol B.W., ten Kate F.W., ter Schegget J. et al.: "Prediction of recurrent and residual dysplasia by human papillomavirus detection among patients with abnormal cytology". Gynecol. Oncol., 1999, 72 (2), 199.

[52] Nagai Y., Maehama T., Asato T., Kanazawa K.: "Persistence of human papillomavirus infection after therapeutic conization for CIN 3: is it an alarm for disease recurrence?". Gynecol. Oncol., 2000, 79 (2), 294.

[53] Kjellberg L., Wadell G., Bergaman F., Isaksson M., Angstrom T., Dillner J.: "Regular disappearance of the human papillomavirus genome after conization of cervical dysplasia by carbon dioxide laser". Am. J. Obstet. Gynecol., 2000, 183 (5), 1238.

[54] Lin C.T., Tseng C.J., Lai C.H., Hsueh S., Huang K.G., Huang HJ. et al.: "Value of human papillomavirus deoxyribonucleic acid testing after conization in the prediction of residual disease in the subsequent hysterectomy specimen". Am. J. Obst et. Gynecol., 2001, 184 (5), 940.

[55] Nobbenhuis M.A.E., Meijer CJ.LM., van der Brule AJ.C., Rozendaal L., Voorhorst F.J., Risse E.K. et al.: "Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia". Br. J. Cancer, 2001, 84 (6), 796.

[56] Kucera E., Sliutz G., Czervenka K., Breitenecker G., Leodolter S., Reinthaller A.: "Is high-risk human papillomavirus infection associated with cervical intraepithelial neoplasia eliminated after conization by large-loop excision of the transformation zone?". Eur. J. Obstet. Gynecol. Reprod. Biol., 2001, 100 (1), 72.

[57] Acladious N., Sutton C.J., Manda] D., Zaklama M., Hopkins R., Kitchener H.C.: "Persistent human papillomavirus infection and smoking increase risk of failure of treatment of CIN". Int. J. Cancer, 2002, 98 (3), 435..